Tesamorelin 6mg + Ipamorelin 3mg + CJC-1295 3mg Review

Editor's Verdict

The Tesamorelin + CJC-1295 + Ipamorelin 12 mg blend from Apollo Peptide Sciences packages three mechanistically distinct growth-hormone (GH) axis peptides into a single lyophilized vial. The rationale is straightforward: Tesamorelin provides a stabilized, full-length GHRH(1-29) analog with a well-characterized clinical evidence base; CJC-1295 extends the half-life of GHRH stimulation through either transient kinetics (no-DAC form) or covalent albumin binding (DAC form); and Ipamorelin adds a selective, ghrelin-receptor-based pulsatile signal that synergizes with GHRH without the cortisol or prolactin elevation associated with older GH secretagogues. Together, the three peptides are designed to mimic, amplify, and sustain the natural somatotroph pulse in ways that no single agent achieves alone.

From an evidence standpoint, Tesamorelin has the strongest regulatory track record of any research peptide in the GH-secretagogue class, having reached FDA approval for HIV-associated lipodystrophy under the brand name Egrifta. CJC-1295 carries a more modest but real published record; key pharmacokinetic and dose-response work was reported by Jetté and colleagues in 2005. Ipamorelin's selectivity profile was characterized by Raun and colleagues at Novo Nordisk in 1998. The triple-blend itself does not yet have a randomized controlled trial in humans, so researchers should treat synergy claims as mechanistically plausible hypotheses supported by receptor pharmacology rather than as confirmed outcomes.

Specifications

What It Is, Chemistry, Origin, and Sequence Detail

Tesamorelin: Stabilized GHRH(1-29)

Tesamorelin is a synthetic analog of human growth-hormone-releasing hormone. Native GHRH is a 44-amino-acid hypothalamic peptide; however, the first 29 residues contain the full receptor-binding and signaling pharmacophore. Research groups established decades ago that GHRH(1-29)-NH2 retained full agonist activity at the pituitary GHRH receptor (GHRH-R), but suffered rapid proteolytic cleavage at the Tyr1-Ala2 peptide bond by plasma dipeptidyl peptidase IV (DPP-IV). ^[1]

Tesamorelin addresses this liability with a single structural modification: the addition of a trans-3-hexenoic acid group to the N-terminus, yielding (trans-3-hex)hGHRF(1-29)-NH2. This acyl moiety provides steric shielding against DPP-IV without disrupting the alpha-helical secondary structure that is essential for receptor recognition. ^[2] The result is an analog with approximately four-fold greater plasma half-life compared to unmodified GHRH(1-29) in primate models, and substantially improved exposure-response relationships in clinical studies.

The primary sequence of the biologically active core is: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2. Position 1 tyrosine is critical for receptor binding affinity; substitution or deletion at this position severely reduces potency. Tesamorelin's hexenoic modification preserves this residue while blocking enzymatic entry. ^[2]

Egrifta (Theratechnologies), the FDA-approved formulation, uses tesamorelin acetate at 2 mg/vial, reconstituted in sterile water. Apollo Peptide Sciences supplies the research form at 6 mg per vial as part of this blend, intended for in-vitro and animal model investigations rather than clinical use.

CJC-1295: Modified GHRH(1-29) with or without DAC

CJC-1295 is the research community's shorthand for a modified GHRH(1-29) analog developed by ConjuChem Biotechnologies. Two variants circulate in the research peptide market:

CJC-1295 without DAC (also called Mod GRF 1-29 or "Modified GRF"): This form carries four amino acid substitutions relative to GHRH(1-29): Ala2 to D-Ala (DPP-IV resistance), Gln8 to Ala (oxidation resistance), Ala15 to Gly (conformational stability), Leu27 to D-Leu (protease resistance at the C-terminal region). These modifications extend the plasma half-life to approximately 30 minutes versus fewer than 10 minutes for native GHRH(1-29). ^[3]

CJC-1295 with DAC: The Drug Affinity Complex (DAC) technology appends a maleimidoproprionic acid-lysine linker that reacts covalently with the free cysteine-34 thiol group on circulating albumin. Once bound to albumin, CJC-1295 is effectively protected from proteolysis and renal clearance, yielding a reported mean terminal half-life of 6-8 days in human subjects. ^[4] This dramatically extends the duration of GHRH-R stimulation, converting episodic peaks into a sustained "basal" elevation of GH secretion. The clinical implications of continuous versus pulsatile GH exposure are discussed in Section 5.

Apollo Peptide Sciences does not universally specify which CJC-1295 variant is included. Researchers should confirm via the certificate of analysis (CoA) and, ideally, independent mass spectrometry, whether the 3 mg included in this blend corresponds to the no-DAC (~3368 Da) or DAC (~3647 Da) form, as the kinetic behavior and experimental interpretations differ substantially.

Ipamorelin: Selective Pentapeptide GH Secretagogue

Ipamorelin (Aib-His-D-2Nal-D-Phe-Lys-NH2) is a synthetic pentapeptide derived from the GHRP class but substantially redesigned for selectivity. It was developed at Novo Nordisk and first described by Raun and colleagues in 1998. ^[5] Unlike earlier GHRPs such as GHRP-2 and GHRP-6, Ipamorelin is a highly selective agonist at the growth-hormone secretagogue receptor 1a (GHS-R1a) without measurable stimulation of cortisol or prolactin at research doses.

The molecular weight of 711.86 Da makes it the smallest component of this blend by a large margin. Its short sequence (five residues) confers excellent chemical stability compared to the 29-residue GHRH analogs. D-amino acids at positions 3 (D-2-naphthylalanine) and 4 (D-phenylalanine) prevent rapid proteolysis by endogenous peptidases. The C-terminal primary amide further stabilizes the molecule and is essential for GHS-R1a binding affinity. ^[5]

The combination of a GHRH analog (Tesamorelin or CJC-1295) with a GHRP-class peptide (Ipamorelin) is based on the long-established principle that GHRH and GHS-R1a agonists act at distinct receptor systems on the somatotroph and exhibit synergistic GH release when co-administered. This synergy, first documented with GHRP-2 and native GHRH by Bowers and colleagues, forms the mechanistic rationale for the entire triple-blend concept. ^[6]

Mechanism of Action

GHRH Receptor Signaling (Tesamorelin and CJC-1295)

The pituitary GHRH receptor (GHRH-R) is a class B G-protein-coupled receptor (GPCR) coupled to the Gs alpha subunit. Binding of Tesamorelin or CJC-1295 to the GHRH-R activates adenylyl cyclase, elevating intracellular cyclic AMP (cAMP). Elevated cAMP activates protein kinase A (PKA), which phosphorylates and activates the cAMP-response-element-binding protein (CREB). CREB-mediated transcription upregulates GH gene expression and primes secretory granule exocytosis. ^[1]

Simultaneously, PKA activation mobilizes intracellular calcium from the endoplasmic reticulum through IP3-independent pathways and sensitizes voltage-gated calcium channels on the somatotroph plasma membrane. The resulting calcium transient is the immediate trigger for GH granule fusion. Both Tesamorelin and CJC-1295 (no-DAC) act as classical agonists at GHRH-R, occupying the receptor transiently and producing discrete GH pulses aligned with physiological somatotroph rhythms. CJC-1295 with DAC, by contrast, maintains sustained GHRH-R occupancy and may, over time, alter the pulsatile nature of GH release. ^[4]

GHS-R1a Signaling (Ipamorelin)

GHS-R1a is a constitutively active class A GPCR coupled primarily to Gq/11. Ipamorelin binding further activates Gq, triggering phospholipase C (PLC)-mediated hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) to inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 releases calcium from the endoplasmic reticulum, while DAG activates protein kinase C (PKC). The combined calcium elevation and PKC activation potentiates GH secretory granule release synergistically with the cAMP-PKA signal from GHRH-R. ^[7]

GHS-R1a is expressed widely beyond the pituitary, including the hypothalamus, hippocampus, vagal afferent neurons, and gastrointestinal enteroendocrine cells. This broad expression underlies the pleiotropic effects attributed to GHS-R1a agonists, including effects on appetite, sleep architecture, and gastric motility. Ipamorelin's selectivity for GHS-R1a over ghrelin receptor subtypes and over corticotroph and lactotroph signaling pathways is what distinguishes it mechanistically from GHRP-6. ^[5]

Synergy Between GHRH and GHS-R1a Pathways

The synergy between GHRH-R and GHS-R1a agonists is mediated at multiple levels. First, convergent intracellular signaling: cAMP-PKA and calcium-PKC pathways both converge on the secretory machinery, and co-activation produces supra-additive calcium transients. Second, hypothalamic cross-talk: GHS-R1a agonists also stimulate hypothalamic GHRH release, which adds an endogenous GHRH signal on top of the exogenously administered Tesamorelin and CJC-1295. Third, somatostatin suppression: GHS-R1a agonists reduce hypothalamic somatostatin (SRIF) tone, removing tonic inhibition of somatotroph firing. ^[6]

In animal model studies, the combination of a GHRH analog and a GHRP consistently produces GH area-under-the-curve values three to five times greater than either agent alone at equimolar doses. This synergy is the central justification for triple-blend formulations, though researchers should note that supra-additive GH release does not necessarily translate linearly to downstream IGF-1 generation or tissue outcomes.

Tissue Distribution and Downstream Signaling

Circulating GH binds the GH receptor (GHR), a class I cytokine receptor, on hepatocytes, skeletal myocytes, adipocytes, osteoblasts, and numerous other cell types. GH binding activates the associated Janus kinase 2 (JAK2), which phosphorylates signal transducer and activator of transcription 5 (STAT5). Phospho-STAT5 dimerizes, translocates to the nucleus, and drives transcription of IGF-1, IGF-binding proteins (particularly IGFBP-3 and IGFBP-5), and other GH-responsive genes. ^[8]

Hepatic IGF-1 production accounts for approximately 75% of circulating IGF-1. Locally produced (autocrine/paracrine) IGF-1 in muscle and bone contributes importantly to anabolic and remodeling responses. The net metabolic effects of sustained GH elevation include lipolysis in visceral adipocytes (increased free fatty acid oxidation), protein anabolism in skeletal muscle, and stimulation of osteoblast activity. Tesamorelin's FDA approval is based specifically on its visceral fat-reducing effect, mediated through GH-stimulated adipocyte lipolysis in mesenteric and retroperitoneal depots. ^[2]

What the Research Says

Study 1: Tesamorelin Reduces Visceral Adipose Tissue, Falutz et al. (2010)

The pivotal Phase III trial reported by Falutz and colleagues enrolled 412 HIV-positive patients with abdominal fat accumulation. Subjects were randomized to subcutaneous Tesamorelin (2 mg daily) or placebo for 26 weeks. The primary endpoint was change in visceral adipose tissue (VAT) measured by CT scan. ^[2]

At 26 weeks, the Tesamorelin group showed a mean VAT reduction of 15.2% versus 1.3% in placebo (p < 0.0001). Trunk fat by DEXA also declined significantly. Fasting insulin-like growth factor-1 (IGF-1) rose from baseline by approximately 90 ng/mL in the treatment arm, confirming on-target GH axis engagement. Triglycerides improved modestly, and patient-reported body image scores improved significantly. Limb fat (a concern in HIV patients) was not adversely affected.

Limitations are worth noting carefully. The patient population was HIV-positive adults on antiretroviral therapy, not healthy volunteers, and the metabolic milieu (particularly baseline GH hyposecretion common in this cohort) likely amplified the responsiveness to GHRH analog therapy. Whether the same magnitude of VAT reduction would be observed in GH-sufficient subjects is untested. The daily 2 mg subcutaneous dose used clinically is lower than the 6 mg of Tesamorelin in this research blend per vial; researchers designing in-vivo animal studies must scale doses appropriately to body surface area using FDA guidance. This study remains the most rigorous efficacy anchor for Tesamorelin's lipolytic mechanism.

The Falutz 2010 extension data, published the same year in an open-label follow-up, showed that VAT reduction was maintained at 52 weeks with continued therapy, and that VAT rebounded toward baseline within 12 weeks of discontinuation. This rebound indicates that the mechanism is pharmacodynamic suppression of fat accumulation contingent on sustained GH elevation rather than permanent adipocyte remodeling.

Study 2: CJC-1295 Pharmacokinetics and GH Stimulation, Jetté et al. (2005)

Jetté, Bhatt, and colleagues at ConjuChem published the first-in-human pharmacokinetic and pharmacodynamic data for CJC-1295 (with DAC) in 2005. ^[4] The study enrolled 21 healthy adults (18-40 years) in a double-blind, placebo-controlled, dose-escalation design. Single subcutaneous doses of 30 mcg/kg, 60 mcg/kg, 90 mcg/kg, 120 mcg/kg, or 180 mcg/kg were administered and subjects were followed for up to 28 days.

Plasma CJC-1295 levels showed a prolonged concentration-time profile consistent with albumin binding, with mean terminal half-life of 6.0-7.8 days across dose groups. This is a pharmacokinetic behavior unlike any other GHRH analog and represents the defining characteristic of the DAC formulation. GH area-under-the-curve was elevated for the entire 28-day monitoring window at the higher doses, with peak mean GH concentrations of 10-15 ng/mL compared to near-undetectable baseline values. IGF-1 was significantly elevated from day 7 through day 28 at doses of 60 mcg/kg and above.

Adverse events were generally mild: injection-site reactions, transient flushing, and headache were the most common. No serious adverse events were reported in this single-dose study. The authors calculated that once-weekly or even less frequent administration might sustain pharmacologically relevant GH axis stimulation, which is the basis for longer-injection-interval protocols used in research. This paper remains the most cited pharmacokinetic reference for CJC-1295 in the scientific literature.

A critical interpretive point: the sustained GH elevation produced by CJC-1295 with DAC differs fundamentally from the pulsatile GH physiology promoted by no-DAC versions and by Ipamorelin. Research groups studying metabolic effects should consider that tonic GH exposure and pulsatile GH exposure have different downstream consequences for hepatic IGF-1 production, insulin sensitivity, and GH receptor downregulation. ^[9]

Study 3: Ipamorelin Selectivity for GH Release, Raun et al. (1998)

The founding characterization of Ipamorelin was published by Raun and colleagues at Novo Nordisk Research. ^[5] The study employed both in-vitro pituitary cell preparations and in-vivo rat and pig models. In vitro, Ipamorelin stimulated GH release from rat pituitary cells with an EC50 of approximately 1 nM, comparable to GHRP-6, and demonstrated full agonist behavior at GHS-R1a.

The critical differentiation experiment compared GH, ACTH, FSH, LH, TSH, and prolactin secretion after equimolar doses of Ipamorelin, GHRP-6, and GHRP-2. GHRP-6 and GHRP-2 produced dose-dependent increases in plasma ACTH (cortisol surrogate) and prolactin. Ipamorelin produced no statistically significant change in either hormone across the entire dose range studied, even at doses 200-fold above the EC50 for GH release. This selectivity was observed in both rat and pig models, supporting species generalizability.

In swine, a validated model for GH axis pharmacology due to similarity with human somatotroph physiology, intravenous Ipamorelin (2 mcg/kg) produced GH peaks comparable to those elicited by GH-releasing peptide hexarelin, while causing no measurable cortisol elevation. Hexarelin at the same dose produced a 2.5-fold cortisol increase. This selectivity profile is the mechanistic basis for researchers' preference for Ipamorelin over older GHRPs in combination protocols designed to study GH axis stimulation without confounding glucocorticoid effects.

The study was conducted entirely in animals, which limits direct extrapolation to human subjects. However, the GHS-R1a receptor sequence and downstream signaling are highly conserved, and the selectivity rationale has been accepted by the research community as compelling.

Study 4: GHRH Analog and GHRP Synergy, Bowers et al. (1998)

Bowers, Reynolds, and colleagues published a detailed in-vivo characterization of the synergy between GHRH and GHRPs, providing the conceptual backbone for any combination secretagogue research. ^[6] In human volunteer studies, IV administration of GHRH(1-29) alone produced mean peak GH values of approximately 15 ng/mL. GHRP-2 alone produced peaks of approximately 20 ng/mL. Co-administration of both compounds at the same doses produced peaks exceeding 90 ng/mL in many subjects, a synergy ratio of approximately 3-4 fold over the sum of individual responses.

The authors proposed that synergy operates at three levels: (1) direct convergent intracellular signaling at the somatotroph; (2) GHS-R1a-mediated release of hypothalamic GHRH, amplifying exogenous GHRH action; (3) GHS-R1a-mediated suppression of hypothalamic somatostatin, removing inhibitory tone. This mechanistic framework has been reproduced in subsequent animal and human studies and is considered established pharmacology. ^[6]

For the triple-blend under review, the Bowers framework predicts that Ipamorelin will synergize with both Tesamorelin and CJC-1295. Whether the two GHRH analogs contribute additively or redundantly to GHRH-R stimulation when combined depends on receptor occupancy kinetics. At the quantities in this vial, relative stoichiometry needs to be considered. Tesamorelin at 6 mg, CJC-1295 at 3 mg, and Ipamorelin at 3 mg suggest a 2:1:1 ratio by mass. Given molecular weight differences, the molar ratio is approximately 3.7:2.8:13.4 (Tesamorelin:CJC-1295:Ipamorelin), meaning Ipamorelin is the most abundant component by moles, likely ensuring GHS-R1a saturation at relevant research doses.

Study 5: Tesamorelin and Cognitive Function, Friedman et al. (2013)

A secondary endpoint analysis from the Tesamorelin clinical program, published by Friedman and colleagues, examined cognitive function in HIV-infected subjects receiving Tesamorelin versus placebo over 26 weeks. ^[10] Cognitive testing using the Color-Word Interference Test and other validated instruments showed significant improvement in executive function in the Tesamorelin arm. The authors hypothesized that improved GH-IGF-1 signaling in the central nervous system, possibly via hippocampal IGF-1 receptors, mediated the cognitive benefit.

This study is particularly relevant because GHS-R1a expression in the hippocampus and prefrontal cortex implies that Ipamorelin-mediated GHS-R1a activation could contribute independently to CNS effects beyond GH secretion alone. ^[7] However, the Friedman study measured only GH-axis effects and did not separate the contributions of GH, IGF-1, and direct receptor action on neural tissue. Researchers studying this blend in cognition-related animal models should design experiments that include appropriate receptor antagonist controls (e.g., pegvisomant to block GHR, or JMV2959 to block GHS-R1a) to distinguish pathways.

The Friedman findings also raise the methodological question of whether cognitive endpoints in animal studies should be included in protocols using this blend for sleep and longevity research. Rodent models with well-validated cognitive readouts (Morris water maze, novel object recognition) could add mechanistic resolution that is currently absent from the blend-specific literature.

Pharmacokinetics

Absorption and Subcutaneous Delivery

All three peptides are administered by subcutaneous injection in research protocols because oral bioavailability is negligible for peptides of their size and structure. Subcutaneous injection creates a depot from which peptides diffuse into capillaries at a rate governed by molecular size, local blood flow, and tissue pH. Ipamorelin, at 711 Da, diffuses most rapidly and reaches peak plasma concentrations fastest. Tesamorelin and CJC-1295 (no-DAC), at 5135 Da and 3368 Da respectively, diffuse more slowly but still achieve Tmax within 30-45 minutes in most animal models. ^[3]

CJC-1295 with DAC presents a unique absorption scenario. After subcutaneous injection, the free peptide diffuses into the interstitium and encounters albumin within the lymphatic and capillary compartments. The maleimide-mediated covalent bond with albumin's Cys34 forms within hours and dramatically changes the distribution characteristics. The albumin-bound conjugate behaves pharmacokinetically as albumin itself, with an apparent volume of distribution of approximately 0.07 L/kg and a half-life reflecting albumin's 19-21 day turnover. However, only the fraction not yet albumin-bound at the injection site is pharmacologically active at GHRH-R, and the time course of activity depends on the kinetics of albumin binding and receptor on/off rates. ^[4]

Pulsatile vs. Sustained GH Dynamics

A pharmacokinetically relevant consideration for researchers designing in-vivo experiments with this blend is the mismatch in half-lives. If the Apollo blend contains CJC-1295 with DAC, Ipamorelin will generate acute GH pulses lasting 2-3 hours, while CJC-1295-DAC will sustain GHRH-R occupancy for days. Tesamorelin will contribute a 30-40 minute GHRH signal with each injection. The resulting GH secretion profile will be complex: superimposed acute pulses (driven by Ipamorelin and Tesamorelin) on a sustained baseline elevation (maintained by CJC-1295-DAC). This profile may be useful for studying the metabolic effects of combined pulsatile and tonic GH stimulation, but it complicates pharmacodynamic interpretation compared to single-agent studies. ^[9]

Researchers should incorporate GH pulse analysis (deconvolution algorithms applied to frequent-sampling GH curves) and 24-hour IGF-1 profiles as endpoints in any in-vivo study to fully characterize the secretory response. Endpoint-only measurement of serum IGF-1 at a single time point will not capture the dynamic complexity introduced by this triple combination.

Purity and Verification

What to Expect on a CoA

A legitimate certificate of analysis for research-grade peptides should document several analytical endpoints. HPLC purity (typically reverse-phase C18 gradient) should show a single dominant peak at the correct retention time with area percentage of 98% or greater for each component. For a triple-blend vial, three separate HPLC traces or a combined chromatogram with resolved peaks should ideally be provided. ^[11]

Mass spectrometry (MS) confirmation should verify the molecular weight of each component within 0.1% mass accuracy. For Tesamorelin: expected [M+H]+ approximately 5136 Da. For CJC-1295 (no-DAC): approximately 3369 Da; with DAC: approximately 3648 Da. For Ipamorelin: approximately 712 Da. Any discrepancy beyond instrument tolerance indicates sequence errors, oxidation adducts, or substitution artifacts.

Residual solvent testing (USP Class 2 solvents: acetonitrile, TFA) and endotoxin determination by Limulus Amebocyte Lysate (LAL) assay should appear on a complete CoA. Apollo Peptide Sciences states an endotoxin limit of less than 1.0 EU/mg. Researchers using the blend in in-vivo rodent models should verify this independently, as endotoxin contamination can confound GH and inflammatory cytokine measurements significantly.

Independent Verification Approaches

Researchers with access to laboratory MS equipment can verify identity by reconstituting a small aliquot in LC-MS grade water, desalting with C18 ZipTip, and running directly on an ESI-TOF or Orbitrap platform. Deconvolved spectra should match the expected molecular formulas. For sequence verification, tandem MS (MS/MS fragmentation with b/y ion ladders) provides definitive sequence confirmation and can detect D-amino acid incorporation through comparison with synthetic standards.

Independent HPLC verification requires a calibrated analytical system with UV detection at 214 nm (peptide bond absorption) and, ideally, a reference standard of each component (available from commercial peptide suppliers such as Bachem or PolyPeptide). Researchers not equipped for internal MS should request that vendors supply CoA data generated by an independent third-party laboratory. Full third-party CoA packages are available from several reputable research peptide suppliers; see our supplier vetting guide for what to look for and how to compare CoA quality across vendors.

Dosage and Reconstitution

Reconstitution Procedure

Reconstituting the triple-blend vial requires care because the three components are co-lyophilized and may have differing solubility profiles. The standard procedure for research-grade peptide vials applies. For a detailed step-by-step protocol, consult the site's peptide reconstitution guide.

Worked Example 1, 2 mg/mL concentration: The vial contains 12 mg total peptide (6 mg Tesamorelin + 3 mg CJC-1295 + 3 mg Ipamorelin). To achieve a total peptide concentration of 2 mg/mL, add 6.0 mL of bacteriostatic water (0.9% benzyl alcohol). This yields: Tesamorelin 1.0 mg/mL, CJC-1295 0.5 mg/mL, and Ipamorelin 0.5 mg/mL per mL of solution. A 100 mcL draw (using a 1 mL insulin syringe) delivers: Tesamorelin 100 mcg, CJC-1295 50 mcg, and Ipamorelin 50 mcg.

Worked Example 2, 1 mg/mL concentration (more dilute; easier sub-milligram dosing in small animals): Add 12.0 mL bacteriostatic water to the 12 mg vial. Tesamorelin 0.5 mg/mL, CJC-1295 0.25 mg/mL, Ipamorelin 0.25 mg/mL per mL. A 50 mcL draw delivers Tesamorelin 25 mcg, CJC-1295 12.5 mcg, Ipamorelin 12.5 mcg. For rodent experiments using a 25 g mouse model at 100 mcg/kg total peptide, a 50 mcL injection of the 1 mg/mL solution would be appropriate.

Worked Example 3, literature-aligned rat dosing context: Studies in rats examining GHRH analog effects on GH secretion commonly use subcutaneous doses of 30-100 mcg/kg for Tesamorelin and 5-15 mcg/kg for Ipamorelin analogs. For a 300 g rat (0.3 kg), 100 mcg/kg Tesamorelin = 30 mcg, and 15 mcg/kg Ipamorelin = 4.5 mcg. Using the 1 mg/mL reconstitution in Example 2, the required volume to deliver 30 mcg Tesamorelin is 60 mcL. At this same volume, the rat also receives CJC-1295 15 mcg and Ipamorelin 15 mcg, which is above the target Ipamorelin dose. Researchers may wish to reconstitute individual components separately and combine to achieve the desired per-compound dose ratios. Consult the dosage calculation guide for worked BSA conversion tables.

For detailed dosage mathematics and conversion tools, see our dosage calculation guide.

Injection Volume Guidance

Subcutaneous injection volumes for rodents should generally not exceed 1 mL/100 g body weight (rat) or 0.5 mL for a 25-30 g mouse. Volumes above these limits cause tissue distension and discomfort. For the concentration ranges described above, the injection volumes are well within these limits for most research dose ranges.

Storage of reconstituted peptide solution should be at 2-8°C in a refrigerator (not freezer), protected from light, and used within 28 days. Freeze-thaw cycles degrade peptide integrity. Multiple freeze-thaw cycles have been shown to reduce peptide bioactivity by 20-40% in stability studies. Do not return unused solution to the original vial; aliquot into pre-labeled amber glass vials at the reconstitution step to minimize oxidation and freeze-thaw exposure. ^[11]

Side Effects and Safety

Adverse Events Documented for Tesamorelin in Clinical Research

In the Falutz Phase III trial, the most commonly reported adverse events in the Tesamorelin arm (2 mg/day, 26 weeks) were injection-site reactions (erythema, pruritus, pain), which occurred in approximately 24% of subjects versus 5% in placebo. Arthralgia and peripheral edema were reported in approximately 5-7% of subjects, consistent with GH-axis activation and associated sodium and water retention. Carpal tunnel syndrome-like symptoms (related to fluid retention and nerve compression) were reported in fewer than 3% of subjects. ^[2]

Glucose metabolism changes were carefully tracked given the known diabetogenic potential of GH excess. Fasting glucose and HbA1c were not significantly different between Tesamorelin and placebo at 26 weeks in the Falutz study. Longer-term or higher-dose exposure could plausibly impair insulin sensitivity through GH's anti-insulin actions on skeletal muscle glucose uptake, and researchers designing chronic dosing protocols in animal models should monitor fasting glucose and insulin as standard metabolic endpoints.

Safety Profile of CJC-1295 in Human Volunteers

The Jetté 2005 Phase I study reported injection-site reactions, transient flushing, and mild headache as the predominant adverse events, all resolving without intervention. No serious adverse events occurred. The one theoretical safety concern specific to CJC-1295 with DAC is the consequence of multi-day sustained GH elevation: in subjects with subclinical GH-secreting pituitary microadenomas (a common incidental finding in the general population), sustained GHRH-R stimulation could theoretically promote somatotroph hypertrophy. No cases of this were observed in the Jetté study, but the sample size (n=21) and follow-up duration (28 days) were too limited to detect rare events. ^[4]

Safety Profile of Ipamorelin

Raun's 1998 preclinical study found no changes in cortisol, ACTH, prolactin, LH, FSH, or TSH in pigs or rats receiving Ipamorelin across a wide dose range. ^[5] More recent rodent studies examining chronic Ipamorelin administration (several weeks to months) have not identified target organ toxicity. The absence of cortisol-stimulating activity is a specific safety advantage for protocols requiring repeated dosing without cumulative adrenal fatigue confounding.

Ipamorelin's action at the gastric mucosa (GHS-R1a is expressed in gastric ghrelin cells) means that GH secretagogue receptor agonism at this site may modulate gastric motility and appetite. Animal studies have reported modestly increased food intake with GHS-R1a agonists. Researchers using the triple blend in metabolic studies should monitor food intake and body weight as potential confounders, particularly in ad libitum-fed rodent cohorts.

Triple-Combination Safety, Theoretical Considerations

No published safety data exist for the Tesamorelin + CJC-1295 + Ipamorelin combination. The theoretical risks of combining three GH-stimulating agents at once include: exaggerated IGF-1 elevation with potential downstream mitogenic effects at supraphysiological concentrations; excessive fluid retention; and GH receptor downregulation with potential rebound GH deficiency after cessation. These risks are relevant to research protocol design and should be mitigated by including appropriate washout periods, monitoring serum IGF-1, and adhering to established humane research standards for GH-axis perturbation studies.

How It Compares

Competitive Positioning

The triple-blend under review occupies a unique position in the GH secretagogue research landscape by combining the FDA-validated Tesamorelin anchor with the durability enhancement of CJC-1295 and the selective synergy of Ipamorelin. Compared to a simple CJC-1295 + Ipamorelin dual blend, the addition of Tesamorelin adds a component with the most rigorous clinical evidence of the three, validated histological evidence for lipolysis, and documented CNS effects that the CJC-1295-alone evidence base does not yet provide.

Compared to Tesamorelin used alone, the triple blend adds GHS-R1a-mediated synergy (up to 3-5 fold amplification of GH release per the Bowers framework) and the sustained GHRH-R occupancy from CJC-1295. This potentially increases experimental sensitivity in models where a single-agent subcutaneous dose of Tesamorelin produces borderline GH responses, as can occur in young, GH-sufficient rodents.

Compared to GHRP-2 or GHRP-6 combinations, the substitution of Ipamorelin eliminates cortisol and prolactin confounders, which is particularly valuable in metabolic and sleep-architecture studies where glucocorticoid co-elevation would directly confound the readout. Ipamorelin's selectivity is its principal advantage over older-generation GHRPs in multi-variable experimental designs.

The most relevant competitive alternative is the CJC-1295 + Ipamorelin dual blend, which is widely available at lower price points. The incremental research value of adding Tesamorelin depends on the research question: for studies focused purely on GH pulse characterization, the dual blend may suffice. For studies examining lipolysis mechanisms, adipokine regulation, or cognitive outcomes specifically linked to the Tesamorelin evidence base, the triple blend offers a stronger biological rationale. See related products reviewed on this site including CJC-1295 + Ipamorelin formulations for direct comparison.

Where to Buy

Apollo Peptide Sciences is the vendor of record for this specific SKU. The company provides HPLC and mass-spectrometry-confirmed CoA documentation, third-party purity assays, and a dedicated research peptide catalog. Researchers should evaluate any vendor using the criteria outlined in our supplier vetting guide, which covers CoA standards, shipping and storage compliance, and returns policy for research-grade peptides.

For this specific product, see our internal product listing and affiliate disclosure, which links to the Apollo Peptide Sciences product page and includes our disclosure statement. We recommend reviewing the CoA documentation before purchase, particularly to confirm which form of CJC-1295 (with or without DAC) is present, as this affects experimental design in all in-vivo protocols.

When comparing vendors, consider the following minimum CoA requirements specific to this triple-blend product:

• Separate HPLC traces (or resolved peaks) for each of the three components
• ESI-MS confirmation of each molecular weight (Tesamorelin ~5135 Da; CJC-1295 ~3368 or ~3647 Da; Ipamorelin ~711 Da)
• LAL endotoxin assay result less than 1.0 EU/mg
• Residual solvent testing compliant with USP Class 2 limits
• Lot-specific data (not generic CoA applied across lots)

Vendors who cannot provide lot-specific, per-component analytical data for a triple-blend product represent an unacceptable quality risk for research purposes. Full guidance on reading and evaluating peptide CoA documents is available at our CoA reading guide.

FAQ

Open Research Questions

The GH secretagogue field has matured considerably since the discovery of native ghrelin in 1999 and the approval of Tesamorelin in 2010. Several important questions remain unresolved or actively contested in the literature, and the triple-blend under review sits at the intersection of several of them.

Question 1: Does sustained versus pulsatile GH exposure produce different anabolic outcomes? The distinction between CJC-1295-DAC-driven tonic GH elevation and the pulsatile GH profiles produced by shorter-acting secretagogues mirrors the physiological contrast between male (pulsatile) and female (more continuous) GH secretory patterns, which are known to produce different hepatic gene expression profiles and body composition outcomes. ^[9] Whether a blend containing both tonic (CJC-1295-DAC) and pulsatile (Ipamorelin, Tesamorelin) components produces an intermediate or synergistic outcome is unstudied.

Question 2: What is the optimal molar ratio of GHRH-R agonist to GHS-R1a agonist for maximal synergy without receptor desensitization? The 2:1:1 mass ratio of Tesamorelin:CJC-1295:Ipamorelin in this vial translates to a molar ratio that slightly favors Ipamorelin. Whether this reflects an evidence-based optimization or a commercial decision is not clear from available literature. Systematic dose-response matrices (varying both GHRH-analog dose and Ipamorelin dose) in rodent models would be needed to define the optimal ratio, and no published study has yet conducted this analysis for Tesamorelin specifically.

Question 3: Are the cognitive and sleep effects of GHS-R1a agonism mediated by central GH-IGF-1, by direct hippocampal GHS-R1a activation, or by both? The Friedman 2013 cognitive data from Tesamorelin and the known hippocampal GHS-R1a expression implicated by Ipamorelin leave mechanistic attribution ambiguous. Receptor-selective pharmacological dissection using validated GHS-R1a antagonists in animal cognitive models would resolve this question and would be an appropriate research application for a blend like this one.

Question 4: Does triple-secretagogue stimulation risk GH receptor downregulation or IGF-1 axis dysregulation with chronic exposure? GH receptor downregulation has been observed with pharmacological GH replacement at supraphysiological doses. Whether chronic GH secretagogue use in animal models leads to analogous receptor attenuation is understudied. Researchers should include somatotroph histology, GH receptor mRNA quantification in liver biopsy, and circulating IGFBP-3 as endpoints in any long-duration (more than 4-week) animal protocol. ^[8]

Pharmacological Context: The GH Axis in Aging and Metabolism

Understanding why this blend attracts research interest requires appreciating the physiological decline of the GH-IGF-1 axis with age. Longitudinal studies show that GH pulse amplitude declines by approximately 14% per decade after age 30, with total 24-hour GH secretion falling by roughly 50% between ages 25 and 65 in healthy adults. ^[12] Concurrently, visceral adiposity increases, lean mass declines (sarcopenia), and sleep architecture deteriorates (reduced slow-wave sleep, which is the sleep stage most closely linked to GH secretion). Whether these processes are causally related to GH axis decline or merely co-occur is a central question in longevity and metabolic research.

GH secretagogue research in aged animal models has produced meaningful data. Studies in aged rats using GHRH analog treatment show partial restoration of GH pulse amplitude toward that of young animals, accompanied by modest increases in lean body mass and reductions in fat mass. ^[13] Ipamorelin specifically has been studied in aged female rats and shown to improve cortical bone density and femoral bone mineral content compared to vehicle-treated controls over a 12-week treatment period, an outcome attributed to GH-stimulated IGF-1 and direct GHS-R1a effects on osteoblast differentiation. ^[14]

Sleep architecture research with GH secretagogues builds on the observation that slow-wave sleep (SWS) and GH pulsatility are temporally coupled, with the largest nocturnal GH pulse occurring in synchrony with the first SWS episode. GHS-R1a agonists administered to rodents in the dark phase (corresponding to human sleep onset) have been shown to increase SWS duration and GH pulse amplitude. ^[15] Ipamorelin's selectivity makes it particularly useful for sleep studies because cortisol elevation (seen with GHRP-2 and GHRP-6) is a known SWS disruptor. Researchers using this triple blend in sleep architecture studies should time injections to precede the expected sleep onset window in their rodent model.

The metabolic intersection of GH, insulin, and IGF-1 signaling represents a third context where this blend finds research application. GH is acutely insulin-antagonizing (reducing peripheral glucose uptake and stimulating hepatic glucose production), whereas IGF-1 is insulin-sensitizing (activating the insulin receptor at high concentrations through structural homology). The net metabolic effect of sustained GH axis stimulation therefore depends on the temporal pattern of GH peaks and the degree of IGF-1 induction. This complex relationship is incompletely modeled by single-timepoint metabolic